Informação sobre produto
Nome:
Trelagliptin
Sinónimos:
- (R)-2-[[6-(3-Aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]methyl]-4-fluorobenzonitrile
- 2-[[6-[(3R)-3-Amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile
- (R)-2-[[6-(3-AMinopiperidin-1-yl)-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl]Methyl]-4-fluorobenzonitrile
- Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluoro-
Descrição:
Trelagliptin is a potent, selective and orally active agonist of the glucagon-like peptide-1 receptor (GLP-1R) that improves glucose homeostasis in patients with type 2 diabetes. Trelagliptin has been shown to increase insulin secretion and reduce postprandial hyperglycemia. The drug binds to GLP-1Rs on the surface of beta cells in the pancreas. This binding stimulates cAMP production, leading to increased insulin release from pancreatic beta cells. Trelagliptin is chemically stable in human serum, exhibiting no significant changes after incubation for up to 72 hours at 37°C.
Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
Biosynth
Armazenamento a longo prazo:
Notas:
Propriedades químicas
Peso molecular:
357.38 g/mol
Fórmula:
C18H20FN5O2
Pureza:
Min. 95%
MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:
